Your immune system's master switch
Injection · 503A Compounding
Educational content. This page describes Thymosin Alpha-1 for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
Researched and maintained by the PepHookup team. Regulatory status last verified April 12, 2026.
Acts as a toll-like receptor (TLR-9 and TLR-2) agonist on dendritic cells and macrophages, driving MyD88-dependent signaling that matures antigen-presenting cells and promotes T cell and NK cell activity. Most of this mechanistic work is preclinical (cell and animal models).[1][2][3]
Studied for decades in chronic hepatitis B and C. Evidence is mixed: some randomized trials reported higher virological response, including a 26-week course that cleared HBV DNA and HBeAg in 40.6% of patients versus 9.4% of untreated controls, while a US Phase III trial did not reach statistical significance.[4][5][6]
A 2015 meta-analysis of 12 controlled trials in 1,480 sepsis patients found lower all-cause mortality with thymosin alpha-1 (pooled risk ratio 0.68). The authors urged caution because the included trials were small and of limited quality.[7]
A retrospective study of severe COVID-19 reported lower mortality, restored CD4+ and CD8+ T cell counts, and reduced T cell exhaustion markers (PD-1, Tim-3). Ex vivo work in post-acute (long COVID) patients suggests it helps rebalance a dysregulated immune response.[8][9]
Investigated alongside chemotherapy and immunotherapy to support anti-tumor immunity. A historical review summarizes preclinical and clinical experience, though randomized evidence remains limited.[10]
Thymosin alpha-1 (thymalfasin, marketed as Zadaxin) is a naturally occurring 28-amino acid peptide originally isolated from the thymus gland by Dr. Allan Goldstein and colleagues in the 1970s. The thymus is responsible for T cell maturation, and thymosin alpha-1 is one of its key hormonal products regulating immune development and function.
Thymalfasin is approved in more than 35 countries for indications including chronic hepatitis B, as a vaccine adjuvant, and as a broader immunomodulatory agent. In the United States it is not FDA-approved but holds orphan drug designation for several indications, including chronic active hepatitis B and hepatocellular carcinoma. It is one of the more extensively studied peptide therapeutics, and a defining feature is bidirectional immunomodulation: it can strengthen weakened responses while helping rein in excessive inflammation.
Thymosin alpha-1 functions in large part as a toll-like receptor (TLR) agonist, engaging TLR-9 and TLR-2 on dendritic cells and macrophages. This activates MyD88-dependent signaling that, in laboratory models, triggers IKK and p38 MAPK phosphorylation and drives NF-kappaB and AP-1 to produce cytokines such as IL-6, IL-10, and IL-12.
It promotes dendritic cell maturation, upregulating MHC class I and II and co-stimulatory molecules to enhance antigen presentation. Through TLR-9 and the type I interferon pathway it also activates indoleamine 2,3-dioxygenase (IDO), which generates regulatory T cells and IL-10. It supports T cell maturation from precursors into functional helper and cytotoxic cells.
That IDO-linked regulatory arm is the basis for its distinctive bidirectional behavior: in immunosuppression it tends to upregulate effector functions, while in hyperinflammation it can favor regulatory T cells and IL-10 to dampen excess. Much of this signaling has been mapped in animal and cell models rather than human trials.
Your immune system's master switch
Thymosin alpha-1 engages innate immunity largely through TLR-9 and TLR-2, triggering MyD88-dependent cascades that drive cytokine production and upregulate antigen-presenting molecules on dendritic cells. Via TLR-9 and type I interferon signaling it also activates IDO, generating regulatory T cells. This dual output underlies its bidirectional immunomodulation, supporting suppressed immunity while helping temper hyperinflammation. Most of this mechanism is established in preclinical models.
Complete virological response (HBV DNA and HBeAg clearance) at 18 months was 40.6% in the 26-week arm and 26.5% in the 52-week arm versus 9.4% in untreated controls. The 26-week comparison was significant (P=.004); the 52-week comparison was not (P=.068).
Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS · Hepatology, 27(5):1383-7 (1998) · PubMed
Thymosin alpha-1 1.6 mg SC twice weekly for 6 months produced a complete response in 14% versus 4% on placebo, a difference that did not reach statistical significance (P=.084). The authors concluded the results did not confirm efficacy seen in other studies.
Mutchnick MG, Lindsay KL, Schiff ER, et al. · J Viral Hepat, 6(5):397-403 (1999) · PubMed
Lower all-cause mortality with thymosin alpha-1 (pooled risk ratio 0.68, 95% CI 0.59-0.78). Findings were interpreted cautiously given the small size and limited quality of included trials.
Li C, Bo L, Liu Q, Jin F · Int J Infect Dis, 33:90-6 (2015) · PubMed
Lower mortality (11.1% vs 30.0%, P=.044), restoration of CD4+ and CD8+ T cell counts, and reduced T cell exhaustion markers (PD-1, Tim-3).
Liu Y, Pan Y, Hu Z, et al. · Clin Infect Dis, 71(16):2150-2157 (2020) · PubMed
start low, go slow
Subcutaneous (standard)
Subcutaneous (acute/critical)
Subcutaneous (standard): Approved dosing pattern studied in viral hepatitis
Subcutaneous (acute/critical): Pattern used in sepsis and critical-illness studies
The 1.6 mg twice-weekly subcutaneous dose is the most extensively studied and reflects approved dosing in the countries where thymalfasin is marketed.
Some critical-illness protocols use more frequent dosing during an initial intensive phase before tapering to twice weekly.
Peak plasma levels occur roughly 1-2 hours after injection with a short plasma half-life, but downstream immune effects persist longer because they act through cellular activation. Any actual dose is determined by a licensed provider based on the individual.
Thymosin alpha-1 has been studied across many clinical trials and has a long commercial track record in the countries where it is approved. Reported tolerability compares favorably with interferons and interleukins.
Its bidirectional immunomodulation is thought to contribute to safety, since it does not typically provoke uncontrolled immune activation.
Periodic bloodwork including a CBC is reasonable during use. In hepatitis B, ALT flares may reflect beneficial immune-mediated viral clearance rather than harm.
| Peptide | Primary Use | Administration | Cycle Length | Key Differentiator |
|---|---|---|---|---|
| Thymosin Alpha-1 | Immune Support | Injection | 6-12 months (chronic) / short courses (acute) | Bidirectional immunomodulation that can strengthen suppressed immunity while helping temper hyperinflammation; approved as a pharmaceutical in 35+ countries |
| Glutathione | Antioxidant & Detoxification | IV, Oral, Sublingual, Topical | Ongoing supplementation | The body's own master antioxidant, with controlled human data showing oral and sublingual forms can raise body stores and immune markers |
| KPV | Anti-Inflammatory & Wound Healing | Injection, Oral, Topical, Nasal | 4 to 8 weeks | One of the smallest anti-inflammatory peptides, blocking NF-kB nuclear import via PepT1-mediated uptake without melanocortin receptor binding, cAMP elevation, or pigmentation |
| Cathelicidin LL-37 | Chronic Wound Healing & Antimicrobial | Topical | 4 weeks (twice weekly application) | The only human cathelicidin. A single endogenous peptide that combines wound-healing, angiogenic, and broad-spectrum antimicrobial activity through overlapping FPR2/ALX and EGFR pathways, balanced against documented autoimmune cautions. |
The FDA placed this substance in Category 2 of the 503A bulk drug substances evaluation, flagging significant safety risks. 503A compounding carries FDA enforcement risk, so most pharmacies decline to prepare it and many physicians hesitate to prescribe it.
Nomination withdrawn September 2024, then reviewed by PCAC on December 4, 2024. PCAC voted against inclusion on the 503A bulks list. FDA cited inadequate safety data and immunogenicity concerns. Remains ineligible for 503A compounding despite the procedural removal from the formal Category 2 list. Not among the 12 peptides HHS withdrew from Category 2 in April 2026.
PCAC reviewed and recommended against inclusion on 503A bulks list
Removed from Category 2 (nomination withdrawn); remains listed under 'other significant safety risks'
Placed in 503A Category 2 with significant safety risks identified
Last verified April 12, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
Looking into Thymosin Alpha-1? Find a provider who knows this peptide and can walk you through your options.
Find a ProviderA tripeptide antioxidant central to cellular redox, detoxification, and immune function.
Produced endogenously and supplemented via IV, injection, or oral routes; clinical evidence remains mixed.
A 3-residue α-MSH fragment with selective anti-inflammatory activity.
Studied for IBD, colitis, and wound healing; acts independently of melanocortin receptor binding.
A 37-residue antimicrobial peptide from the human cathelicidin family.
Broad roles in innate immunity and wound healing; named in the April 2026 HHS Category 2 withdrawal for PCAC re-evaluation.
“Advanced peptide therapies and personalized luxury care for optimal health, vitality, and longevity.”
Vetted providers offering Thymosin Alpha-1.